{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:36:49Z","timestamp":1792856209705,"version":"4.5.0"},"reference-count":74,"publisher":"Georg Thieme Verlag KG","issue":"01","license":[{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>People with nonsevere hemophilia (PWNSH) are phenotypically more diverse than those with severe hemophilia. Perceptions relating to a \u201cnonsevere\u201d phenotype have contributed to fewer research initiatives, fewer guidelines on optimal management, and a lack of standards for surveillance and clinical assessment for affected individuals. In many cases, episodes of abnormal bleeding could, if investigated, have led to earlier diagnosis. Furthermore, the major recent developments in therapy for hemophilia have largely focused on severe disease and, as a group, PWNSH have not been included in many key clinical trials. Benefiting people with severe disease, innovative replacement therapies have generally targeted factor levels that are above those present in a large proportion of PWNSH. Therapeutic advances can lead to improvement in phenotype for people with severe hemophilia over that currently experienced by many PWNSH. As a result, we are approaching a point where PWNSH may, in many countries, have a higher risk of bleeding and restriction in lifestyle than those with severe disease but with more limited therapeutic options. Given the multiple major advances in treatment for people with hemophilia, it is timely to review the aspects of nonsevere disease, to ensure equity in care and management for all individuals with this condition.<\/jats:p>","DOI":"10.1055\/s-0044-1786358","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T22:31:37Z","timestamp":1715466697000},"page":"058-067","source":"Crossref","is-referenced-by-count":6,"title":["Nonsevere Hemophilia: The Need for a Renewed Focus and Improved Outcomes"],"prefix":"10.1055","volume":"51","author":[{"given":"Gerard","family":"Dolan","sequence":"additional","affiliation":[{"name":"Centre for Haemostasis and Thrombosis, St Thomas' Comprehensive Care Centre, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Fijnvandraat","sequence":"additional","affiliation":[{"name":"Paediatric Haematology, Emma Children's Hospital, and UMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Lenting","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, INSERM, H\u00e9mostase Inflammation Thrombose HITh U1176, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Catarino","sequence":"additional","affiliation":[{"name":"Immunochemotherapy Department, Congenital Coagulopathies Comprehensive Care Centre, Santa Maria University Hospital, Lisbon University, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Lavin","sequence":"additional","affiliation":[{"name":"Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland"},{"name":"National Coagulation Centre, St. James' Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Factor Think Tank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,5,11]]},"reference":[{"issue":"S 04","key":"ref1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/hae.14531","article-title":"Therapeutic and technological advancements in haemophilia care: quantum leaps forward","volume":"28","author":"M Lewandowska","year":"2022","journal-title":"Haemophilia"},{"issue":"S 06","key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd ed","volume":"26","author":"A Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"S 03","key":"ref3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/hae.14094","article-title":"Women and girls with haemophilia: lessons learned","volume":"27","author":"R d'Oiron","year":"2021","journal-title":"Haemophilia"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3390\/jcm12041368","article-title":"Mild and moderate hemophilia A: neglected conditions, still with unmet needs","volume":"12","author":"G Castaman","year":"2023","journal-title":"J Clin Med"},{"issue":"12","key":"ref5","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.3390\/jcm11123322","article-title":"Challenges in the diagnosis and management of non-severe hemophilia","volume":"11","author":"E Boeriu","year":"2022","journal-title":"J Clin Med"},{"issue":"06","key":"ref6","first-page":"535","article-title":"Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management","volume":"16","author":"G Benson","year":"2018","journal-title":"Blood Transfus"},{"issue":"05","key":"ref7","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1365-2516.2004.00955.x","article-title":"The impact of unaware carriership on the clinical presentation of haemophilia","volume":"10","author":"P E MacLean","year":"2004","journal-title":"Haemophilia"},{"issue":"S 05","key":"ref8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1365-2516.2010.02306.x","article-title":"Mild haemophilia: a disease with many faces and many unexpected pitfalls","volume":"16","author":"K Peerlinck","year":"2010","journal-title":"Haemophilia"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1097\/MBC.0000000000000821","article-title":"Clinical pattern of hemophilia and causes of variability","volume":"30","author":"M E Mingot-Castellano","year":"2019","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"14","key":"ref10","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/bloodadvances.2022007620","article-title":"The bleeding phenotype in people with nonsevere hemophilia","volume":"6","author":"F R Kloosterman","year":"2022","journal-title":"Blood Adv"},{"issue":"S 01","key":"ref11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1538-7836.2007.02520.x","article-title":"How to estimate bleeding risk in mild bleeding disorders","volume":"5","author":"F Rodeghiero","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2516.2007.01648.x","article-title":"Bleeding scores in inherited bleeding disorders: clinical or research tools?","volume":"14","author":"A Tosetto","year":"2008","journal-title":"Haemophilia"},{"issue":"09","key":"ref13","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","article-title":"ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders","volume":"8","author":"F Rodeghiero","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.transci.2018.06.003","article-title":"Application of the ISTH bleeding score in hemophilia","volume":"57","author":"M Borhany","year":"2018","journal-title":"Transfus Apheresis Sci"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"100047","DOI":"10.1016\/j.rpth.2023.100047","article-title":"Bleeding phenotype in nonsevere hemophilia by International Society on Thrombosis and Haemostasis bleeding assessment tool, bleeding frequency, and the joint status","volume":"7","author":"J Rejt\u0151","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/hae.13089","article-title":"Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study","volume":"22","author":"P D James","year":"2016","journal-title":"Haemophilia"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood-2006-10-050435","article-title":"Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV","volume":"110","author":"S C Darby","year":"2007","journal-title":"Blood"},{"issue":"06","key":"ref19","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/jth.13693","article-title":"Mortality caused by intracranial bleeding in non-severe hemophilia A patients","volume":"15","author":"J I Loomans","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref20","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3390\/jcm11071969","article-title":"Intracranial haemorrhage in haemophilia patients is still an open issue: the final results of the Italian EMO.REC Registry","volume":"11","author":"E Zanon","year":"2022","journal-title":"J Clin Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.15256\/joc.2011.1.2","article-title":"Haemophilia and joint disease: pathophysiology, evaluation, and management","volume":"1","author":"K Knobe","year":"2011","journal-title":"J Comorb"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/hae.14201","article-title":"Clinical phenotype of severe and moderate haemophilia: Who should receive prophylaxis and what is the target trough level?","volume":"27","author":"P W Collins","year":"2021","journal-title":"Haemophilia"},{"issue":"S 01","key":"ref23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/hae.14105","article-title":"Non-severe haemophilia: Is it benign? - Insights from the PROBE study","volume":"27","author":"C Chai-Adisaksopha","year":"2021","journal-title":"Haemophilia"},{"issue":"S 01","key":"ref24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/hae.14251","article-title":"Impact of haemophilia on patients with mild-to-moderate disease: results from the P-FiQ and B-HERO-S studies","volume":"27","author":"M Witkop","year":"2021","journal-title":"Haemophilia"},{"key":"ref25","first-page":"s330","article-title":"Outcome in moderate haemophilia","volume":"12","author":"I den Uijl","year":"2014","journal-title":"Blood Transfus"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1111\/jth.15475","article-title":"The factor VIII treatment history of non-severe hemophilia A: COMMENT. Joint damage in adult patients with mild or moderate hemophilia A evaluated with the HEAD-US system","volume":"19","author":"M T \u00c1lvarez Rom\u00e1n","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref27","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1111\/jth.15076","article-title":"The factor VIII treatment history of non-severe hemophilia A","volume":"18","author":"A Abdi","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/jth.15676","article-title":"Joint status of patients with nonsevere hemophilia A","volume":"20","author":"A F Zwagemaker","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/hae.14899","article-title":"Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)","volume":"30","author":"R J M\u00e5seide","year":"2024","journal-title":"Haemophilia"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.thromres.2022.01.010","article-title":"Arthropathy in people with mild haemophilia: exploring risk factors","volume":"211","author":"H De la Corte-Rodriguez","year":"2022","journal-title":"Thromb Res"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/hae.13088","article-title":"Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective","volume":"23","author":"K Fischer","year":"2017","journal-title":"Haemophilia"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jth.15182","article-title":"Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001-2018","volume":"19","author":"S Hassan","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref33","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"G C White II","year":"2001","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref34","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1055\/s-0042-1758870","article-title":"Factor VIII and Factor IX activity measurements for hemophilia diagnosis and related treatments","volume":"49","author":"A E Bowyer","year":"2023","journal-title":"Semin Thromb Hemost"},{"issue":"12","key":"ref35","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1111\/jth.14315","article-title":"The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH","volume":"16","author":"M Makris","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jth.13215","article-title":"A critical appraisal of one-stage and chromogenic assays of factor VIII activity","volume":"14","author":"F Peyvandi","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref37","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtha.2022.11.040","article-title":"Little discrepancy between one-stage and chromogenic factor VIII (FVIII)\/IX assays in a large international cohort of persons with nonsevere hemophilia A and B","volume":"21","author":"A F Zwagemaker","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref38","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jtha.2022.12.013","article-title":"Both one-stage and chromogenic factor VIII assays are required for the diagnosis of mild hemophilia A","volume":"21","author":"S Kitchen","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref39","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/hae.13219","article-title":"Discrepancies between the one-stage clotting assay and the chromogenic assay in haemophilia B","volume":"23","author":"K Kihlberg","year":"2017","journal-title":"Haemophilia"},{"issue":"03","key":"ref40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/bjh.16776","article-title":"Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis","volume":"191","author":"P Baker","year":"2020","journal-title":"Br J Haematol"},{"issue":"06","key":"ref41","doi-asserted-by":"crossref","first-page":"e12777","DOI":"10.1002\/rth2.12777","article-title":"Desmopressin for bleeding in non-severe hemophilia A: suboptimal use in a real-world setting","volume":"6","author":"A F Zwagemaker","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"01","key":"ref42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B","volume":"232","author":"I M Nilsson","year":"1992","journal-title":"J Intern Med"},{"issue":"06","key":"ref43","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/ejh.13610","article-title":"Recombinant factor VIII Fc for the treatment of haemophilia A","volume":"106","author":"C Hermans","year":"2021","journal-title":"Eur J Haematol"},{"issue":"03","key":"ref44","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1111\/hae.14301","article-title":"Haemophilia A patients' medication adherence to prophylaxis with efmoroctocog alfa","volume":"27","author":"V Pitance","year":"2021","journal-title":"Haemophilia"},{"issue":"13","key":"ref45","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood.2020005673","article-title":"Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study","volume":"137","author":"R Klamroth","year":"2021","journal-title":"Blood"},{"issue":"06","key":"ref46","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1111\/hae.14866","article-title":"Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review","volume":"29","author":"L Malec","year":"2023","journal-title":"Haemophilia"},{"issue":"05","key":"ref47","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16704","article-title":"Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B","volume":"190","author":"R Rayment","year":"2020","journal-title":"Br J Haematol"},{"issue":"01","key":"ref48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/hae.14676","article-title":"Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia: a review of the literature","volume":"29","author":"A Iorio","year":"2023","journal-title":"Haemophilia"},{"issue":"03","key":"ref49","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2352-3026(22)00377-5","article-title":"Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study","volume":"10","author":"C N\u00e9grier","year":"2023","journal-title":"Lancet Haematol"},{"issue":"02","key":"ref50","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1016\/S2352-3026(23)00270-3","article-title":"Advancements in haemophilia A and health equity: is it time to redefine severity?","volume":"11","author":"A C Weyand","year":"2024","journal-title":"Lancet Haematol"},{"issue":"S 01","key":"ref52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/hae.14168","article-title":"Identified unmet needs and proposed solutions in mild-to-moderate haemophilia: A summary of opinions from a roundtable of haemophilia experts","volume":"27","author":"C Walsh","year":"2021","journal-title":"Haemophilia"},{"issue":"07","key":"ref53","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1055\/s-0040-1710591","article-title":"von Willebrand factor and factor VIII clearance in perioperative hemophilia A patients","volume":"120","author":"I van Moort","year":"2020","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref54","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1111\/j.1365-2516.2012.02758.x","article-title":"Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies","volume":"18","author":"A Coppola","year":"2012","journal-title":"Haemophilia"},{"issue":"03","key":"ref55","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2141.2007.06657.x","article-title":"Inhibitor development in haemophilia B: an orphan disease in need of attention","volume":"138","author":"D DiMichele","year":"2007","journal-title":"Br J Haematol"},{"issue":"03","key":"ref56","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/rth2.12314","article-title":"Hemophilia management: huge impact of a tiny difference","volume":"4","author":"F Kloosterman","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"ref57","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood-2013-02-483263","article-title":"Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A","volume":"122","author":"C L Eckhardt","year":"2013","journal-title":"Blood"},{"issue":"07","key":"ref58","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/jth.12990","article-title":"Inhibitor development and mortality in non-severe hemophilia A","volume":"13","author":"C L Eckhardt","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref59","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/jth.13711","article-title":"Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study","volume":"15","author":"A S van Velzen","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref60","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1160\/th15-03-0212","article-title":"The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors","volume":"115","author":"A S van Velzen","year":"2016","journal-title":"Thromb Haemost"},{"issue":"19","key":"ref61","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1182\/bloodadvances.2020002626","article-title":"Inhibitors and mortality in persons with nonsevere hemophilia A in the United States","volume":"4","author":"M Y Lim","year":"2020","journal-title":"Blood Adv"},{"issue":"08","key":"ref62","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3390\/ph15080911","article-title":"Immunogenicity of current and new therapies for hemophilia A","volume":"15","author":"A NL Prezotti","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"06","key":"ref63","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/bjh.16490","article-title":"Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case-control study","volume":"189","author":"A S van Velzen","year":"2020","journal-title":"Br J Haematol"},{"issue":"01","key":"ref64","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1160\/TH14-11-0940","article-title":"Inhibitors in nonsevere haemophilia A: outcome and eradication strategies","volume":"114","author":"A S van Velzen","year":"2015","journal-title":"Thromb Haemost"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/20406207211007058","article-title":"Expert opinion on the UK standard of care for haemophilia patients with inhibitors: a modified Delphi consensus study","volume":"12","author":"K Khair","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"02","key":"ref66","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1111\/hae.14186","article-title":"Genetic causes of haemophilia in women and girls","volume":"27","author":"C H Miller","year":"2021","journal-title":"Haemophilia"},{"issue":"08","key":"ref67","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/jth.15397","article-title":"A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH","volume":"19","author":"K PM van Galen","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref68","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41431-020-00742-4","article-title":"X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers","volume":"29","author":"I Garagiola","year":"2021","journal-title":"Eur J Hum Genet"},{"issue":"06","key":"ref69","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/hae.14422","article-title":"Descriptive analysis of bleeding symptoms in haemophilia carriers enrolled in the ATHNdataset","volume":"27","author":"J Puetz","year":"2021","journal-title":"Haemophilia"},{"issue":"S 01","key":"ref70","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/hae.14193","article-title":"Current challenges for men and women with mild-to-moderate haemophilia","volume":"27","author":"M Rajpurkar","year":"2021","journal-title":"Haemophilia"},{"issue":"02","key":"ref71","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/hae.13376","article-title":"The spectrum of bleeding in women and girls with haemophilia B","volume":"24","author":"J Staber","year":"2018","journal-title":"Haemophilia"},{"issue":"S 04","key":"ref72","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/hae.14535","article-title":"Health issues in women and girls affected by haemophilia with a focus on nomenclature, heavy menstrual bleeding, and musculoskeletal issues","volume":"28","author":"A C Weyand","year":"2022","journal-title":"Haemophilia"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"100826","DOI":"10.1016\/j.blre.2021.100826","article-title":"Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: a systematic review","volume":"49","author":"M C Punt","year":"2021","journal-title":"Blood Rev"},{"issue":"02","key":"ref74","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1055\/a-1141-1252","article-title":"Perinatal Management of Haemophilia","volume":"40","author":"W Streif","year":"2020","journal-title":"Hamostaseologie"},{"issue":"05","key":"ref75","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/hae.14379","article-title":"European principles of care for women and girls with inherited bleeding disorders","volume":"27","author":"K van Galen","year":"2021","journal-title":"Haemophilia"},{"issue":"9824","key":"ref78","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(11)61139-2","article-title":"Modern haemophilia care","volume":"379","author":"E Berntorp","year":"2012","journal-title":"Lancet"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1786358.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T23:37:50Z","timestamp":1737502670000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1786358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,11]]},"references-count":74,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,1,21]]},"published-print":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1786358","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,11]]}}}